---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-038737"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:24:24.445863+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics Q4 2024 net loss $23.2M; cash $313.4M; pipeline milestones set for 2025

## Summary
- Net loss $23.2M in Q4 2024 ($19.4M in Q4 2023); full year 2024 net loss $89.0M ($71.6M in FY2023).
- Cash, cash equivalents and marketable securities $313.4M as of Dec 31, 2024; cash runway into mid-2027.
- R&D expenses $20.7M in Q4 2024 ($17.9M Q4 2023); full year $80.8M ($64.6M FY2023).
- ELVN-001 Phase 1 data expected mid-2025; ELVN-002 Phase 1 data expected H2 2025; FDA orphan drug designation.
- First patient dosed in Japanese Phase 1 trial for ELVN-001; ELVN-002 combination trials enrolling.

## SEC filing metadata
- accession: 0000950170-25-038737
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000095017025038737/0000950170-25-038737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000095017025038737/elvn-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-038737
- JSON: https://secwatch.observer/filing/0000950170-25-038737.json
- Plain text: https://secwatch.observer/filing/0000950170-25-038737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.